Comparative Pharmacology
Head-to-head clinical analysis: CEFOTAN versus CEFZIL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CEFOTAN versus CEFZIL.
CEFOTAN vs CEFZIL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cefotetan is a cephamycin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting peptidoglycan cross-linking, and activating autolytic enzymes.
Cefprozil inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting peptidoglycan cross-linking.
1-2 g IV/IM every 12 hours for 5-10 days; up to 6 g/day for severe infections.
500 mg orally twice daily for 10 days; for uncomplicated skin infections, 250 mg twice daily or 500 mg once daily.
None Documented
None Documented
Terminal elimination half-life: 4.5 hours (intravenous). In patients with renal impairment (CrCl <30 mL/min), half-life extends to approximately 20–30 hours, requiring dose adjustment.
1.2-1.5 hours in healthy adults; prolonged in renal impairment (e.g., up to 6-8 hours in severe renal failure)
Primarily renal (unchanged); ~88% excreted in urine within 24 hours. Biliary/fecal elimination is negligible (<1% as metabolites).
Renal: 80-91% unchanged in urine; biliary/fecal: minimal (<5%)
Category C
Category C
Cephalosporin Antibiotic
Cephalosporin Antibiotic